Last reviewed · How we verify

Travoprost 0.004% BAK-free

Alcon Research · FDA-approved active Small molecule Quality 2/100

Travoprost 0.004% BAK-free is a Small molecule drug developed by Alcon Research. It is currently FDA-approved. Also known as: TRAVATAN® BAK-free.

At a glance

Generic nameTravoprost 0.004% BAK-free
Also known asTRAVATAN® BAK-free
SponsorAlcon Research
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Travoprost 0.004% BAK-free

What is Travoprost 0.004% BAK-free?

Travoprost 0.004% BAK-free is a Small molecule drug developed by Alcon Research.

Who makes Travoprost 0.004% BAK-free?

Travoprost 0.004% BAK-free is developed and marketed by Alcon Research (see full Alcon Research pipeline at /company/alcon-research).

Is Travoprost 0.004% BAK-free also known as anything else?

Travoprost 0.004% BAK-free is also known as TRAVATAN® BAK-free.

What development phase is Travoprost 0.004% BAK-free in?

Travoprost 0.004% BAK-free is FDA-approved (marketed).

Related